A M Issa

Summary

Affiliation: University of Houston
Country: USA

Publications

  1. ncbi Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges
    Amalia M Issa
    UCLA School of Public Health, Room 31 245A CHS, Campus Box 951772, Los Angeles, CA 90095 1772, USA
    Pharmacogenomics 4:647-55. 2003
  2. ncbi Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends
    Amalia M Issa
    Program in Personalized Medicine and Targeted Therapeutics, University of Houston, 300 Technology Building, Houston, TX 77204 4021, USA
    Curr Drug Saf 2:177-85. 2007
  3. ncbi Assessing patient readiness for the clinical adoption of personalized medicine
    A M Issa
    Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, The Methodist Hospital Research Institute, University of Houston, Houston, Texas 77204 4021, USA
    Public Health Genomics 12:163-9. 2009
  4. ncbi The regulation of pharmacogenomics-based drugs and policy making
    Amalia M Issa
    UCLA School of Public Health, CHS Room 31 245A, Box 951772, Los Angeles, CA 90095 1772, USA
    Curr Top Med Chem 4:1455-60. 2004
  5. ncbi Diagnostics and biomarker development: priming the pipeline
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 5:463-9. 2006

Detail Information

Publications5

  1. ncbi Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges
    Amalia M Issa
    UCLA School of Public Health, Room 31 245A CHS, Campus Box 951772, Los Angeles, CA 90095 1772, USA
    Pharmacogenomics 4:647-55. 2003
    ..A critical analysis of some of the methodological design and ethical issues generated by the potential incorporation of pharmacogenomic profiling into pharmacosurveillance programs is presented...
  2. ncbi Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends
    Amalia M Issa
    Program in Personalized Medicine and Targeted Therapeutics, University of Houston, 300 Technology Building, Houston, TX 77204 4021, USA
    Curr Drug Saf 2:177-85. 2007
    ..A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts...
  3. ncbi Assessing patient readiness for the clinical adoption of personalized medicine
    A M Issa
    Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, The Methodist Hospital Research Institute, University of Houston, Houston, Texas 77204 4021, USA
    Public Health Genomics 12:163-9. 2009
    ....
  4. ncbi The regulation of pharmacogenomics-based drugs and policy making
    Amalia M Issa
    UCLA School of Public Health, CHS Room 31 245A, Box 951772, Los Angeles, CA 90095 1772, USA
    Curr Top Med Chem 4:1455-60. 2004
    ..Hypothetical vignettes are used to illustrate a number of issues that are challenging to policy makers and the potential impact of pharmacogenomic based drug research and development on the regulatory environment...
  5. ncbi Diagnostics and biomarker development: priming the pipeline
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 5:463-9. 2006
    ..Here, we characterize the pipeline problem for biomarkers and diagnostics, and consider what steps could be taken to solve it...